Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioXcel Therapeutics, Inc. - Common Stock (NQ:BTAI)

0.1115 -0.0255 (-18.61%)
Streaming Delayed Price Updated: 2:47 PM EDT, Sep 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioXcel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Which stocks have an unusual volume on Wednesday? ↗
Via Chartmill
Here are the top movers in Wednesday's session. ↗
Via Chartmill
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
Here are the top movers in Tuesday's session. ↗
Via Chartmill
BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study ↗
Via Stocktwits
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
Tuesday's session: gap up and gap down stocks ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
On Monday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
Friday's session: top gainers and losers ↗
Via Chartmill
Which stocks are experiencing notable movement on Friday? ↗
Via Chartmill
Gapping stocks in Friday's session ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc.
From Levi & Korsinsky, LLP
Via GlobeNewswire
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
News headline image
Why Did BTAI Stock Surge 20% In Pre-Market Today? ↗
BioXcel announced positive Phase 2 results for evaluating treatment for opioid withdrawal symptoms. 
Via Stocktwits
News headline image
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients ↗
BioXcel's Phase 3 trial shows BXCL501 effectively reduces agitation in bipolar and schizophrenia patients, supporting its at-home treatment use. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank? ↗
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Wednesday? ↗
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment ↗
BioXcel's Phase 3 trial shows BXCL501 safely reduces agitation in schizophrenia patients, supporting plans for an FDA label expansion. 
Via Benzinga
News headline image
The market is filled with gapping stocks in Wednesday's session. ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Wednesday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.